Anti-TNF-α Monoclonal Antibody Therapy Improves Anemia through Downregulating Hepatocyte Hepcidin Expression in Inflammatory Bowel Disease

Figure 4

Anti-TNF-α mAb therapy downregulates hepcidin expression in CD patients. 32 patients with A-CD were treated with anti-TNF-α mAb (infliximab, IFX) at weeks 0, 2, and 6. Serum samples were collected from these patients prior to and 12 weeks after the first anti-TNF-α mAb therapy; the levels of hepcidin in the Response group ((a), ) and the Failure group ((b), ) were analyzed by an ELISA. . Unpaired Student’s -tests were performed for statistical analysis.

(a)

(b)